Published in Br J Cancer on June 19, 2007
Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis. J Biol Chem (2012) 1.04
Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med (2012) 1.04
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med (2012) 0.91
Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One (2011) 0.90
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet (2009) 0.86
Comparison of the expression levels of molecular markers among the peripheral area and central area of primary tumor and metastatic lymph node tumor in patients with squamous cell carcinoma of the lung. J Cancer Res Clin Oncol (2015) 0.78
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
Epidermal growth factor. J Biol Chem (1990) 4.79
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol (2005) 3.39
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res (2002) 1.71
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 1.64
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer (2005) 1.52
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol (2005) 1.38
Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol (1992) 1.18
Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. Br J Cancer (2005) 0.98
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res (2003) 0.95
Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol (1992) 0.92
Targeting the epidermal growth factor receptor: an important incremental step in the battle against colorectal cancer. J Clin Oncol (2004) 0.91
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol (2008) 4.27
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer (2012) 1.50
Why is coeliac disease endemic in the people of the Sahara? Lancet (1999) 1.48
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Anti-human versus anti-guinea pig tissue transglutaminase antibodies as the first-level serological screening test for coeliac disease in the general population. Dig Liver Dis (2004) 1.43
[Paraneoplastic syndromes: a review]. Clin Ter (2006) 1.39
Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants. Arch Dis Child (2009) 1.37
Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol (2003) 1.36
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol (2012) 1.28
T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood (2001) 1.26
Synchronous mucosa-associated lymphoid tissue lymphoma and adenocarcinoma of the stomach. Am J Surg Pathol (1997) 1.25
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer (2012) 1.21
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol (2008) 1.19
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer (2013) 1.15
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol (2000) 1.13
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer (2007) 1.07
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer (2013) 1.05
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer (2011) 1.04
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann Oncol (2004) 1.04
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol (2009) 1.02
Localized amyloidosis and gastrointestinal lymphoma: a rare association. Histopathology (1998) 1.02
KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Ann Oncol (2008) 1.01
Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. J Clin Ultrasound (2001) 0.98
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol (2005) 0.97
Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol (2001) 0.97
HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol (2002) 0.96
Primary alveolar soft part sarcoma of the stomach: a case report and review. Pathol Res Pract (2000) 0.95
Early signs of tuberous sclerosis in infancy and childhood. Helv Paediatr Acta (1973) 0.94
Familial Axenfeld-Rieger anomaly, cardiac malformations, and sensorineural hearing loss: a provisionally unique genetic syndrome? Am J Med Genet (2002) 0.94
Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer (2006) 0.94
An intronic mutation in MLH1 associated with familial colon and breast cancer. Fam Cancer (2011) 0.93
Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol (2009) 0.93
Sequence analysis of the hepatitis B virus pre-C region in hepatocellular carcinoma [HCC] and nontumoral liver tissues from HCC patients. Virology (1992) 0.92
Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci (2010) 0.92
High frequency of CagA+ Helicobacter pylori infection in high-grade gastric MALT B-cell lymphomas. J Pathol (1998) 0.92
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2008) 0.91
MOMO syndrome: a possible third case. Clin Dysmorphol (2000) 0.89
Turner's syndrome in Italy: familial characteristics, neonatal data, standards for birth weight and for height and weight from infancy to adulthood. Acta Paediatr (1994) 0.89
Storage cells of spleen and bone marrow in thalassemia: an ultrastructural study. Blood (1973) 0.88
Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors. Oncol Rep (2000) 0.88
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol (2012) 0.88
Multifocal early gastric cancer: morphology and histogenesis. Pathol Res Pract (1986) 0.85
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Support Care Cancer (2015) 0.85
Small benign tumors of the esophagus: radiological diagnosis with double-contrast examination. Gastrointest Radiol (1983) 0.85
A clinicopathological study of 152 surgically treated primary gastric lymphomas with survival analysis of 109 high grade tumours. J Clin Pathol (2002) 0.85
Giant axonal neuropathy. Endocrinological and histological studies. Eur J Pediatr (1985) 0.85
Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Support Care Cancer (2014) 0.85
[Protein-losing gastroenteropathy (Ménétrier's disease) in childhood: a report of 3 cases]. Pediatr Med Chir (1996) 0.84
Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? Dig Liver Dis (2003) 0.84
Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer (2005) 0.84
Central precocious puberty and abnormal chromosomal patterns. Endocr Pathol (2000) 0.84
Urinary tract infection in full-term newborn infants: risk factor analysis. Rev Hosp Clin Fac Med Sao Paulo (2000) 0.83
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study. Ann Oncol (1999) 0.83
Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure (2005) 0.83
Effectiveness of the CRCAPRO program in identifying patients suspected for HNPCC. Clin Genet (2007) 0.82
Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer (2005) 0.81
Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Crit Rev Oncol Hematol (2001) 0.81
Centrocytic-like lymphoma associated with localized amyloidosis of the large intestine. Virchows Arch (1994) 0.81
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer (2006) 0.81
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. Br J Cancer (2003) 0.81
Long-term follow-up in early gastric cancer: evaluation of prognostic factors. J Pathol (1995) 0.80
Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Rev Anticancer Ther (2001) 0.80
Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann Oncol (2006) 0.80